Literature DB >> 34332039

Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.

Ning Zhang1, Xiaohui Hua2, Huailu Tu1, Jingxia Li1, Zhuo Zhang1, Costa Max3.   

Abstract

Epithelial mesenchymal transition (EMT) is highly correlated with metastasis during cancer development. Although previous studies have revealed that ISO is able to inhibit cancer cell invasion and stem-cell properties, little is known about the effects of ISO on EMT markers. The present study explores the potential regulation of ISO on EMT, leading to the inhibition of migration and invasion of bladder cancer cells. We found that ISO inhibited Vimentin, one of the EMT markers, in the invasive bladder cancer cell lines U5637 and T24T. ISO reduced Vimentin protein level by increasing the expression of METTL14. On the other hand, ISO upregulated the METTL14 mRNA by activating the transcription factor FOXO3a. The results demonstrate that ISO inhibits invasion by affecting the EMT marker and offer a novel insight into understanding the upregulation of METTL14 by ISO.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  EMT; FOXO3a; ISO; METTL14; Vimentin

Mesh:

Substances:

Year:  2021        PMID: 34332039      PMCID: PMC9161647          DOI: 10.1016/j.canlet.2021.07.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  55 in total

1.  New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer.

Authors:  Xiaohui Hua; Jiheng Xu; Xu Deng; Jiawei Xu; Jingxia Li; David Q Zhu; Junlan Zhu; Honglei Jin; Zhongxian Tian; Haishan Huang; Qin-Shi Zhao; Chuanshu Huang
Journal:  Cancer Lett       Date:  2018-08-16       Impact factor: 8.679

2.  FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.

Authors:  Miranda S C Wilson; Jan J Brosens; Helma D C Schwenen; Eric W-F Lam
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

3.  Stilbene dimers from the lianas of Gnetum hainanense.

Authors:  K S Huang; Y H Wang; R L Li; M Lin
Journal:  Phytochemistry       Date:  2000-08       Impact factor: 4.072

4.  Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.

Authors:  Karine Belguise; Shangqin Guo; Gail E Sonenshein
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

5.  Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases.

Authors:  Ping Wang; Katelyn A Doxtader; Yunsun Nam
Journal:  Mol Cell       Date:  2016-06-30       Impact factor: 17.970

6.  Isorhapontigenin Suppresses Interleukin-1β-Induced Inflammation and Cartilage Matrix Damage in Rat Chondrocytes.

Authors:  Yongzhuang Ma; Chang Tu; Wei Liu; Yifan Xiao; Hua Wu
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

Review 7.  RNA N6-methyladenosine modification in cancers: current status and perspectives.

Authors:  Xiaolan Deng; Rui Su; Hengyou Weng; Huilin Huang; Zejuan Li; Jianjun Chen
Journal:  Cell Res       Date:  2018-04-23       Impact factor: 25.617

8.  EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.

Authors:  Li Wang; Abdel Saci; Peter M Szabo; Scott D Chasalow; Mireia Castillo-Martin; Josep Domingo-Domenech; Arlene Siefker-Radtke; Padmanee Sharma; John P Sfakianos; Yixuan Gong; Ana Dominguez-Andres; William K Oh; David Mulholland; Alex Azrilevich; Liangyuan Hu; Carlos Cordon-Cardo; Hélène Salmon; Nina Bhardwaj; Jun Zhu; Matthew D Galsky
Journal:  Nat Commun       Date:  2018-08-29       Impact factor: 14.919

9.  METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.

Authors:  Dandan Yi; Ru Wang; Xianbiao Shi; Lei Xu; Yiminu'er Yilihamu; Jianfeng Sang
Journal:  Oncol Rep       Date:  2020-02-24       Impact factor: 3.906

10.  A Stilbenoid Isorhapontigenin as a Potential Anti-Cancer Agent against Breast Cancer through Inhibiting Sphingosine Kinases/Tubulin Stabilization.

Authors:  Lalita Subedi; Mahesh Kumar Teli; Jae Hyuk Lee; Bhakta Prasad Gaire; Mi-Hyun Kim; Sun Yeou Kim
Journal:  Cancers (Basel)       Date:  2019-12-05       Impact factor: 6.639

View more
  6 in total

Review 1.  Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer.

Authors:  Qiang Liu
Journal:  Front Genet       Date:  2022-01-11       Impact factor: 4.599

2.  Induction of RAC1 protein translation and MKK7/JNK-dependent autophagy through dicer/miR-145/SOX2/miR-365a axis contributes to isorhapontigenin (ISO) inhibition of human bladder cancer invasion.

Authors:  Xiaohui Hua; Daimin Xiang; Mengxin Guo; Xiaohui Qian; Ruifan Chen; Tengda Li; Zhongxian Tian; Jiheng Xu; Chao Huang; Qipeng Xie; Chuanshu Huang
Journal:  Cell Death Dis       Date:  2022-08-31       Impact factor: 9.685

Review 3.  The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer.

Authors:  Bin Shi; Wei-Wei Liu; Ke Yang; Guan-Min Jiang; Hao Wang
Journal:  Mol Cancer       Date:  2022-08-16       Impact factor: 41.444

Review 4.  Role of m6A writers, erasers and readers in cancer.

Authors:  Zhen Fang; Wentong Mei; Chang Qu; Jiongdi Lu; Liang Shang; Feng Cao; Fei Li
Journal:  Exp Hematol Oncol       Date:  2022-08-09

5.  Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer.

Authors:  Tianhang Li; Tianyao Liu; Zihan Zhao; Yuchen Pan; Xinyan Xu; Yulin Zhang; Shoubin Zhan; Shengkai Zhou; Wenjie Zhu; Hongqian Guo; Rong Yang
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 6.  Functions, mechanisms, and therapeutic implications of METTL14 in human cancer.

Authors:  Qian Guan; Huiran Lin; Lei Miao; Huiqin Guo; Yongping Chen; Zhenjian Zhuo; Jing He
Journal:  J Hematol Oncol       Date:  2022-02-03       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.